CONMED Beheer

Beheer criteriumcontroles 3/4

De CEO CONMED is Curt Hartman, benoemd in Jul2014, heeft een ambtstermijn van 10.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.76M, bestaande uit 12.2% salaris en 87.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde € 6.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 9.3 jaar.

Belangrijke informatie

Curt Hartman

Algemeen directeur

US$7.8m

Totale compensatie

Percentage CEO-salaris	12.2%
Dienstverband CEO	10.3yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	9.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Curt Hartman's beloning veranderd ten opzichte van CONMED's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$132m
Jun 30 2024	n/a	n/a	US$99m
Mar 31 2024	n/a	n/a	US$82m
Dec 31 2023	US$8m	US$950k	US$64m
Sep 30 2023	n/a	n/a	US$58m
Jun 30 2023	n/a	n/a	US$88m
Mar 31 2023	n/a	n/a	-US$94m
Dec 31 2022	US$8m	US$946k	-US$81m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	US$68m
Dec 31 2021	US$9m	US$918k	US$63m
Sep 30 2021	n/a	n/a	US$62m
Jun 30 2021	n/a	n/a	US$54m
Mar 31 2021	n/a	n/a	US$13m
Dec 31 2020	US$6m	US$888k	US$10m
Sep 30 2020	n/a	n/a	US$311k
Jun 30 2020	n/a	n/a	US$431k
Mar 31 2020	n/a	n/a	US$34m
Dec 31 2019	US$6m	US$842k	US$29m
Sep 30 2019	n/a	n/a	US$29m
Jun 30 2019	n/a	n/a	US$28m
Mar 31 2019	n/a	n/a	US$31m
Dec 31 2018	US$5m	US$791k	US$41m
Sep 30 2018	n/a	n/a	US$72m
Jun 30 2018	n/a	n/a	US$73m
Mar 31 2018	n/a	n/a	US$71m
Dec 31 2017	US$3m	US$753k	US$55m

Compensatie versus markt: De totale vergoeding ($USD 7.76M ) Curt } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.61M ).

Compensatie versus inkomsten: De vergoeding van Curt is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Curt Hartman (60 yo)

10.3yrs

Tenure

US$7,764,615

Compensatie

Mr. Curt R. Hartman serves as the Director of CONMED Corporation since October 31, 2024 and Chief Executive Officer and President of CONMED Corporation since November 09, 2014, He served as Chairman of the...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Curt Hartman	President	10.3yrs	US$7.76m	0.30% € 6.3m
Todd Garner	Executive VP	6.8yrs	US$2.87m	0.00073% € 15.2k
Patrick Beyer	Chief Operating Officer	less than a year	US$3.30m	0.035% € 730.7k
Richard Glaze	Chief Information Officer	no data	geen gegevens	geen gegevens
Hollie Foust	General Counsel & Corporate Secretary	no data	geen gegevens	geen gegevens
Peter Shagory	Executive Vice President of Strategy & Corporate Development	9.5yrs	geen gegevens	0.012% € 250.9k
Shanna Cotti-Osmanski	Executive VP of Information Technology & CIO	4.7yrs	geen gegevens	geen gegevens
John Ferrell	Executive Vice President of Human Resources	1.9yrs	geen gegevens	0.0023% € 47.4k
David Murray	President of ConMed Electrosurgery	20.3yrs	US$572.33k	geen gegevens
Johonna Pelletier	VP of Tax & Treasurer	9.6yrs	geen gegevens	0.0043% € 89.0k
Kimberly Lockwood	Interim Corporate Controller	less than a year	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EC8 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Curt Hartman	President	10.7yrs	US$7.76m	0.30% € 6.3m
John Workman	Independent Director	9.3yrs	US$257.37k	0.066% € 1.4m
David Bronson	Independent Director	9.3yrs	US$264.87k	0.054% € 1.1m
Brian Concannon	Independent Director	11.3yrs	US$257.37k	0.031% € 651.8k
LaVerne Council	Independent Director	4.9yrs	US$257.37k	0.012% € 241.3k
Martha Aronson	Independent Chair of the Board	8.8yrs	US$292.37k	0.045% € 940.9k
Charles Farkas	Independent Director	10.3yrs	US$249.87k	0.066% € 1.4m
Barbara Schwarzentraub	Independent Director	5.2yrs	US$264.87k	0.017% € 358.9k

9.3yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EC8 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.3 jaar).

CONMED Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

CONMED Corporation, Annual General Meeting, May 22, 2024

Insider recently sold €151k worth of stock

Chairman of the Board recently sold €433k worth of stock

Recent updates

Investor sentiment improves as stock rises 17%

New minor risk - Earnings quality

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings released: EPS: US$1.59 (vs US$0.52 in 3Q 2023)

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation to Report Q3, 2024 Results on Oct 30, 2024

Upcoming dividend of US$0.20 per share

Second quarter dividend of US$0.20 announced

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

Second quarter 2024 earnings released: EPS: US$0.97 (vs US$0.45 in 2Q 2023)

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation to Report Q2, 2024 Results on Jul 31, 2024

Upcoming dividend of US$0.20 per share

First quarter dividend of US$0.20 announced

CONMED Corporation Declares Quarterly Cash Dividend, Payable on July 5, 2024

First quarter 2024 earnings released: EPS: US$0.64 (vs US$0.06 in 1Q 2023)

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation, Annual General Meeting, May 22, 2024

CONMED Corporation to Report Q1, 2024 Results on Apr 24, 2024

Upcoming dividend of US$0.20 per share

Fourth quarter dividend of US$0.20 announced

Full year 2023 earnings released: EPS: US$2.10 (vs US$2.68 loss in FY 2022)

CONMED Corporation Declares Quarterly Cash Dividend, Payable on April 5, 2024

Full year 2023 earnings released: EPS: US$2.10 (vs US$2.68 loss in FY 2022)

CONMED Corporation Provides Financial Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 16%

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2024

Third quarter 2023 earnings released: EPS: US$0.52 (vs US$1.51 in 3Q 2022)

CONMED Corporation Updates Third Quarter Guidance for 2023

CONMED Corporation to Report Q3, 2023 Results on Oct 25, 2023

Upcoming dividend of US$0.20 per share at 0.7% yield

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2023

Second quarter 2023 earnings released: EPS: US$0.45 (vs US$5.65 loss in 2Q 2022)

CONMED Corporation Revises Earnings Guidance for the Full Year 2023

CONMED Corporation to Report Q2, 2023 Results on Jul 26, 2023

Upcoming dividend of US$0.20 per share at 0.6% yield

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2023

Insider recently sold €151k worth of stock

First quarter 2023 earnings released: EPS: US$0.06 (vs US$0.51 in 1Q 2022)

Chairman of the Board recently sold €433k worth of stock

Upcoming dividend of US$0.20 per share at 0.8% yield

Full year 2022 earnings released: US$2.68 loss per share (vs US$2.15 profit in FY 2021)

CONMED Corporation Provides Earnings Guidance for the Full Year 2023

CONMED Corporation to Report Q4, 2022 Results on Feb 02, 2023

Now 21% undervalued after recent price drop

CONMED Corporation Announces Management Changes

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2023

Insufficient new directors

CONMED Corporation Provides Revenue Guidance for the Full Year 2023

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$1.51 (vs US$0.51 in 3Q 2021)

CONMED Corporation Revises Earnings Guidance for the Full Year 2022

CONMED Corporation to Report Q3, 2022 Results on Oct 26, 2022

Insufficient new directors

Chairman of the Board recently sold €329k worth of stock

Upcoming dividend of US$0.20 per share

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2022

CONMED Corporation (NYSE:CNMD) completed the acquisition of Biorez, Inc.

CONMED Corporation (NYSE:CNMD) completed the acquisition of Biorez, Inc.

CONMED Corporation (NYSE:CNMD) has entered into a definitive agreement to acquire Biorez, Inc. for $250 million.

CONMED Corporation (NYSE:CNMD) has entered into a definitive agreement to acquire Biorez, Inc. for $250 million.

Second quarter 2022 earnings released: US$5.65 loss per share (vs US$0.46 profit in 2Q 2021)

CONMED Corporation Revises Earnings Guidance for the Full Year 2022

CONMED Corporation to Report Q2, 2022 Results on Jul 27, 2022

CONMED Corporation(NYSE:CNMD) dropped from Russell 2000 Dynamic Index

CONMED Corporation (NYSE:CNMD) completed the acquisition of In2Bones Global, Inc.

Upcoming dividend of US$0.20 per share

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2022